Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2015

01-03-2015 | Original Article

Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females

Authors: S. Tariq, S. Tariq, S. S. Alam, M. Baig

Published in: Osteoporosis International | Issue 3/2015

Login to get access

Abstract

Summary

A significant change in serum leptin level and no change in homocysteine were observed with ibandronate treatment. No correlation of homocysteine and leptin was found with bone mass density (BMD). Results indicate that ibandronate reduces serum leptin levels but how does it help in reducing the osteoporosis. It needs to be explored.

Introduction

The current study was planned to determine the effects of ibandronate on serum homocysteine and leptin levels in postmenopausal osteoporotic females and to correlate these with BMD.

Methods

Forty-two newly diagnosed and untreated postmenopausal osteoporotic females were selected on the basis of their BMD (BMD < −2.5) from Orthopaedic Out Patient Department of Shaikh Zayed Hospital, Lahore, Pakistan, and 36, age and BMI matched non-osteoporotic postmenopausal females, were also selected as a control group. Baseline physical and biochemical parameters were compared. In osteoporotic patients, changes in circulating leptin and homocysteine levels were studied after 6 months of therapy with ibandronate (150 mg). The collected data were analyzed on SPSS 16.

Results

There was no significant difference observed in the mean value of all baseline parameters except BMD in both groups. After 6 months of treatment with ibandronate (150 mg), a significant change was observed in serum leptin levels (19.48 ± 1.60 ng/ml vs. 14.09 ± 0.85 ng/ml, p < 0.002), while no considerable change observed in serum homocysteine levels (16.22 ± 0.95 μmol/l vs. 16.80 ± 1.03 μmol/l, p < 0.63). Serum leptin was found significantly correlated with anthropometric parameters. No correlation of serum leptin and homocysteine was found with BMD (r = 0.09, p value = 0.54; r = −0.17, p value = 0.27).

Conclusion

Our results show that ibandronate reduces serum leptin levels while it has no effect on serum homocysteine levels. Further studies are needed to explain how the decrease in serum leptin level may help in reducing the progression of osteoporosis.
Literature
1.
National institutes of health consensus development panel on osteoporosis, prevention, diagnosis and therapy (2001). JAMA 285 (6):785–795
2.
Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int Suppl 2:S8–S17CrossRef
3.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475CrossRefPubMed
4.
Baig LA, Karim SA (2006) Age at menopause, and knowledge of and attitudes to menopause, of women in Karachi, Pakistan. J Br Menopause Soc 12:71–74CrossRefPubMed
5.
6.
McLean RR, Jacques PF, Selhub J et al (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350(20):2042–2049CrossRefPubMed
7.
van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SM et al (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033–2041CrossRefPubMed
8.
Tyagi N, Vacek TP, Fleming JT, Vacek JC, Tyagi SC (2011) Hyperhomocysteinemia decreases bone blood flow. Vasc Health Risk Manag 7:31–35PubMedCentralPubMed
9.
LeBoff MS, Narweker R, LaCroix A et al (2009) Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 94:1207–1213CrossRefPubMedCentralPubMed
10.
Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A (2003) Relation of homocysteine, folate and vitamin B12 to bone mineral density of postmenopausal women. Bone 33:956–959CrossRefPubMed
11.
Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease. Am J Med 118:1250–1255CrossRefPubMed
12.
Ducy P, Amling M, Takeda S et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207CrossRefPubMed
13.
Karsenty G (2001) Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 56:401–415CrossRefPubMed
14.
Cornish J, Callon KE, Bava U et al (2002) Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175:405–415CrossRefPubMed
15.
Chan JL, Mantzoros CS (2005) Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 366:74–85CrossRefPubMed
16.
Hamrick MW, Pennington C, Newton D, Xie D, Isales C (2004) Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376–383CrossRefPubMed
17.
Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630–1638PubMed
18.
Holloway WR, Collier FM, Aitken CJ et al (2002) Leptin inhibits osteoclast generation. J Bone Miner Res 17:200–209CrossRefPubMed
19.
Scotece M, Conde J, Vuolteenaho K et al (2014) Adipokines as drug targets in joint and bone disease. Drug Discov Today 19:241–258CrossRefPubMed
20.
Brusin JH, Clung MC (2009) Update on bone densitometry. Radiol technol 81:153BD–170BDPubMed
21.
Miller PD, McCalung MR, Stakkestad JA, Luckey M, Reginster JY, Reckor RR et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Mineral Res 20(8):1315–1322CrossRef
22.
Cakmak A, Posaci C, Dogan E, Caliskan S, Guclu S, Altunyurt S (2005) Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am J Obstet Gynecol 193:347–351CrossRefPubMed
23.
Lambrinoudaki IV, Christodoulakos GE, Economou EV et al (2008) Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. Maturitas 59:62–71CrossRefPubMed
24.
Lavoie H, Taylor A, Sharpless J, Anderson E, Strauss C, Hall J (1999) Effects of short-term hormone replacement on serum leptin levels in postmenopausal women. Clin Endocrinol 51(4):415–422CrossRef
25.
Elbers JM, de RooGW P-SC et al (1999) Effect of administration of 17 beta-oestradiol on serum leptin levels in healthy postmenopausal women. Clin Endocrinol 51:449–454CrossRef
26.
Sebastian-Ochoa AS, Fernandez-Garcıa DF, Reyes-Garcıa R et al (2012) Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate. Menopause 19(2):172–177CrossRefPubMed
27.
Kocyigit H, Bal S, Atay A, Koseoglu M, Gurgan A (2013) Plasma leptin values in postmenopausal women with osteoporosis. Bosn J Basic Med Sci 13:192–196PubMed
28.
Shaarawy M, Abassi AF, Hassan H, Salem ME (2003) Relationship between serum leptin concentrations and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis. Fertil Steril 79:919–924CrossRefPubMed
29.
Bonte DC, Ilie AC, Iacob RE et al (2013) The evaluation of the leptin implication in postmenopausal osteoporosis. J Food Agricult Environ 11(1):244–245
30.
Pasco JA, Henry MJ, Kotowitz MA et al (2001) Serum leptin levels are associated with bone mass in non-obese women. J Clin Endocrinol Metab 86(5):1884–1887PubMed
31.
Bart R, Frisch B, von Tresckow E, Bart C (2007) (2007) Bisphosphonates in medical practice: Actions, side effects, and indications. Springer Publishing, USACrossRef
32.
Amling M, Takeda S, Karsenty GA (2000) Neuro (endo) crine regulation of bone remodeling. Bioessays 22:970–975CrossRefPubMed
33.
Troyanov S, Hebert MJ, Masse M, Vigneault N, Sirois I, Madore F (2003) Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 41:1043–1051CrossRefPubMed
34.
Icin T, Kovacev-Zavisic B, Medic-Stojanoska M et al (2009) Bone resorption and antiresorptive effect of bisphosphonates related to homocysteinaemia. 11th European Congress of Endocrinology, organized by the European society of endocrinology, Istanbul, pp 25–29
35.
Saito M, Fujii K, Marumo K (2006) Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 79:160–168CrossRefPubMed
36.
Perier MA, Gineyts E, Munoz F, Sornay-Rendu E, Delmas PD (2007) Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 18:1329–1336CrossRefPubMed
37.
McLean RR, Hannan MT (2007) B vitamins, homocysteine, and bone disease: Epidemiology and pathophysiology. Curr Osteoporos Rep 5:112–119CrossRefPubMed
38.
Enneman AW, Swart MKA, Zillikens MC et al (2014) The association between plasma homocysteine levels and bone quality and bone mineral density parameters in older persons. Bone 63:141–146CrossRefPubMed
39.
Lateef M, Baig M, Azhar A (2010) Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females. Osteoporos Int 21:751–755CrossRefPubMed
40.
Ibrahim SE, ElShishtawy HF, Helmy A, Galal ZA, Abdel Salam MH (2011) Serum leptin concentration, bone mineral density and bone biochemical markers in a sample of Egyptian women: a possible relationship. The Egyptian Rheumatologist 33(4):171–177CrossRef
41.
Zhao LJ, Jiang H, Papasian CJ et al (2008) Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Min Res 23(1):17–29CrossRef
Metadata
Title
Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females
Authors
S. Tariq
S. Tariq
S. S. Alam
M. Baig
Publication date
01-03-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 3/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2909-9

Other articles of this Issue 3/2015

Osteoporosis International 3/2015 Go to the issue

Original Article

Quantitative ultrasonometry during pregnancy and lactation: a longitudinal study

Original Article

Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis

Original Article

Anthropometric models of bone mineral content and areal bone mineral density based on the bone mineral density in childhood study

Original Article

Hyponatremia and osteoporosis: insights from the Danish National Patient Registry

Original Article

Is thoracolumbar fascia injury the cause of residual back pain after percutaneous vertebroplasty? A prospective cohort study

Original Article

Mediating effects on health-related quality of life in adults with osteoporosis: a structural equation modeling